Newsfeeds - Spark Newswire

5 minute read

FDA
News

Merck & Co Highlights Phase 3 Study On KEYTRUDA Plus Chemotherapy Before Surgery And Continued As A Single Agent After Surgery; Says Shows ‘Statistically Significant Event-Free Survival’ Results

Today, 2:27 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522. The trial investigated

MRK

1 minute read

Merck, Ridgeback Highlight Interim Molnupiravir Data In Non-Hospitalized COVID-19 Patients

By Vandana Singh

Today, 2:27 AM

Merck & Co Inc (NYSE:MRK) and its collaborating partner Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from…

MRK

2 minute read

News

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

By Benzinga Newsdesk

Today, 2:27 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on

MRK

2 minute read

News

Merck Announces Interim Results From Phase 2/3 Studies Of Molnupiravir, An Investigational Oral Antiviral Therapeutic For Mild To Moderate COVID-19, Presented At The European Congress Of Clinical Microbiology & Infectious Diseases

By Benzinga Newsdesk

Today, 2:27 AM

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials

MRK

1 minute read

Disney And Goldman Sachs Lead The DIA Higher Friday

By Henry Khederian

Today, 2:27 AM

U.S. indices were trading higher Friday as markets rebound following a sell-off yesterday over concerns the economic recovery is slowing as the COVID-19 Delta variant spreads.

CAT

2 minute read

Why Galectin Is Soaring And Sigilon Is Sinking Today

By Shanthi Rexaline

Today, 2:27 AM

Galectin Therapeutics Inc. (NASDAQ: GALT) and Sigilon Therapeutics, Inc.

GALT

1 minute read

Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer

By Vandana Singh

Today, 2:27 AM

Galectin Therapeutics Inc (NASDAQ:GALT) has announced top-line clinical data from the extension cohort of Phase 1b trial of Belapectin in combination…

GALT

1 minute read

FDA
News

UPDATE: Merck Says Hetero Has Accumulated Positive Data From Open Label Study Of Molnupiravir, Has Submitted Data To Drugs Controller General Of India

By Benzinga Newsdesk

Today, 2:27 AM

-Reuters

MRK

1 minute read

FDA
News

Merck Issues Statement On Data For Molnupiravir In India: Co. Affirms Commitment To Enabling Global Access To Drug Candidate Through Voluntary License Deals, Ongoing Clinical Program

By Benzinga Newsdesk

Today, 2:27 AM

-Reuters

MRK

1 minute read

OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma

By Vandana Singh

Today, 2:27 AM

OncoSec Medical Inc (NASDAQ:ONCS) will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab)…

BMY